DE60208534T2 - Verwendung von antikörper gegen mag zur behandlung ischämischer schlaganfälle - Google Patents

Verwendung von antikörper gegen mag zur behandlung ischämischer schlaganfälle Download PDF

Info

Publication number
DE60208534T2
DE60208534T2 DE60208534T DE60208534T DE60208534T2 DE 60208534 T2 DE60208534 T2 DE 60208534T2 DE 60208534 T DE60208534 T DE 60208534T DE 60208534 T DE60208534 T DE 60208534T DE 60208534 T2 DE60208534 T2 DE 60208534T2
Authority
DE
Germany
Prior art keywords
antibody
mag
human
immunoglobulin
sequences
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60208534T
Other languages
German (de)
English (en)
Other versions
DE60208534D1 (de
Inventor
Elaine Alison Irving
Mary Vinson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
SmithKline Beecham Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Ltd filed Critical SmithKline Beecham Ltd
Application granted granted Critical
Publication of DE60208534D1 publication Critical patent/DE60208534D1/de
Publication of DE60208534T2 publication Critical patent/DE60208534T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
DE60208534T 2001-02-08 2002-02-08 Verwendung von antikörper gegen mag zur behandlung ischämischer schlaganfälle Expired - Lifetime DE60208534T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0103174.9A GB0103174D0 (en) 2001-02-08 2001-02-08 Novel method of treatment
GB0103174 2001-02-08
PCT/GB2002/000551 WO2002062383A2 (en) 2001-02-08 2002-02-08 Antagonists of myelin-associated glycoprotein and their use in the treatment and/or prevention of neurological diseases

Publications (2)

Publication Number Publication Date
DE60208534D1 DE60208534D1 (de) 2006-03-30
DE60208534T2 true DE60208534T2 (de) 2006-11-30

Family

ID=9908386

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60208534T Expired - Lifetime DE60208534T2 (de) 2001-02-08 2002-02-08 Verwendung von antikörper gegen mag zur behandlung ischämischer schlaganfälle

Country Status (11)

Country Link
US (2) US20040170627A1 (enExample)
EP (2) EP1645285A3 (enExample)
JP (2) JP5005156B2 (enExample)
AT (1) ATE314861T1 (enExample)
AU (1) AU2002229928A1 (enExample)
CY (1) CY1105549T1 (enExample)
DE (1) DE60208534T2 (enExample)
DK (1) DK1357941T3 (enExample)
ES (1) ES2254655T3 (enExample)
GB (1) GB0103174D0 (enExample)
WO (1) WO2002062383A2 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0103174D0 (en) * 2001-02-08 2001-03-28 Smithkline Beecham Plc Novel method of treatment
US20040151721A1 (en) 2001-10-19 2004-08-05 O'keefe Theresa Humanized anti-CCR2 antibodies and methods of use therefor
AR040778A1 (es) * 2002-08-06 2005-04-20 Glaxo Group Ltd Anticuerpos alterados o fragmentos funcionales que se unen a mag (glicoproteina asociada a mielina).
GB0306309D0 (en) * 2003-03-19 2003-04-23 Glaxo Group Ltd Method of treatment
US7959914B2 (en) 2003-05-16 2011-06-14 Acorda Therapeutics, Inc. Methods of reducing extravasation of inflammatory cells
EP3211084B1 (en) * 2003-05-16 2019-03-27 Acorda Therapeutics, Inc. Proteoglycan degrading mutants for treatment of cns
WO2005060368A2 (en) * 2003-12-10 2005-07-07 Millennium Pharmaceuticals, Inc. Humanized anti-ccr2 antibodies and methods of use
JP5189985B2 (ja) 2005-09-26 2013-04-24 アコーダ セラピューティクス、インク． コンドロイチナーゼａｂｃｉ変異体を用いた組成物およびその使用方法
US20100189721A1 (en) * 2007-07-06 2010-07-29 Smithkline Beecham Corporation Antibody formulations
US8974782B2 (en) 2011-02-07 2015-03-10 Glaxo Group Limited Treatment of stroke comprising anti-MAG antibodies

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4873316A (en) * 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
US5250414A (en) * 1988-11-04 1993-10-05 Erziehungsdirektion Of The Canton Zurich Diagnostic methods using neurite growth regulatory factors
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5154924A (en) * 1989-09-07 1992-10-13 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical agent conjugates
US5182107A (en) * 1989-09-07 1993-01-26 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates
US5527527A (en) * 1989-09-07 1996-06-18 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical agent conjugates
GB9403250D0 (en) * 1994-02-21 1994-04-13 Univ Mcgill Therapeutic use of myelin-associated glycoprotein (mag)
US6576607B1 (en) * 1995-04-19 2003-06-10 Acorda Therapeutics Methods using CNS neurite outgrowth modulators
US5792743A (en) * 1995-04-19 1998-08-11 Acorda Therapeutics Method for promoting neural growth comprising administering a soluble neural cell adhesion molecule
US5932542A (en) * 1995-06-27 1999-08-03 Research Foundation Of Cuny, Hunter College Composition and methods using myelin-associated glycoprotein (MAG) and inhibitors thereof
DK1047449T3 (da) * 1997-10-28 2004-01-26 Univ British Columbia Immunologiske præparater og anvendelse deraf til forbigående ændring af myelin i centralnervesystemet hos pattedyr for at fremme neuronal regenerering
WO1999025379A1 (en) * 1997-11-14 1999-05-27 Euro-Celtique, S.A. Modified antibodies with enhanced ability to elicit an anti-idiotype response
WO1999053945A1 (en) * 1998-04-16 1999-10-28 Samuel David Neuron growth inhibitory molecules or derivatives thereof used to immunize mammals thereby promoting axon regeneration
GB9908533D0 (en) * 1999-04-14 1999-06-09 Novartis Ag Organic compounds
GB0103174D0 (en) * 2001-02-08 2001-03-28 Smithkline Beecham Plc Novel method of treatment
US20040002790A1 (en) * 2002-06-28 2004-01-01 Paul Senn Sensitive devices and sensitive applications
AR040778A1 (es) * 2002-08-06 2005-04-20 Glaxo Group Ltd Anticuerpos alterados o fragmentos funcionales que se unen a mag (glicoproteina asociada a mielina).
GB0306309D0 (en) * 2003-03-19 2003-04-23 Glaxo Group Ltd Method of treatment

Also Published As

Publication number Publication date
EP1357941A2 (en) 2003-11-05
AU2002229928A1 (en) 2002-08-19
DE60208534D1 (de) 2006-03-30
JP2008291031A (ja) 2008-12-04
WO2002062383A3 (en) 2003-04-10
EP1645285A2 (en) 2006-04-12
WO2002062383A2 (en) 2002-08-15
ATE314861T1 (de) 2006-02-15
DK1357941T3 (da) 2006-05-01
GB0103174D0 (en) 2001-03-28
US20080014195A1 (en) 2008-01-17
JP2004523538A (ja) 2004-08-05
EP1645285A3 (en) 2010-04-14
CY1105549T1 (el) 2010-07-28
EP1357941B1 (en) 2006-01-04
US20040170627A1 (en) 2004-09-02
ES2254655T3 (es) 2006-06-16
JP5005156B2 (ja) 2012-08-22

Similar Documents

Publication Publication Date Title
US8071731B2 (en) Humanised anti-MAG antibody or functional fragment thereof
DE60116753T2 (de) Humanisierte antikörper gegen den epidermalen wachstumsfaktorrezeptor
TWI329649B (en) Immunoglobulins
DE69934241T2 (de) Agonistische antikörper gegen tie2
US20080014195A1 (en) Antagonists Of Myelin-Associated Glycoprotein And Their Use In The Treatment And/Or Prevention Of Neurological Diseases
DE69828154T2 (de) Anti-alphavbeta3 humanizierte monoklonale antikörper
JP2008539266A (ja) 下位運動ニューロン疾患の治療方法およびそれを含む組成物
US8017115B2 (en) Therapeutical use of anti-myelin associated glycoprotein (MAG) antibodies
RU2303461C9 (ru) Антитела против миелин-ассоциированного гликопротеина (mag)
HK1077206B (en) Anti-mag humanised antibodies and their uses for treating stroke
ZA200500337B (en) Anty-myelin associated glycoprotein (MAG) antibodies
EP1133311A2 (de) BEEINFLUSSUNG DER ANGIOGENESE DURCH CD66a

Legal Events

Date Code Title Description
8364 No opposition during term of opposition